Simultaneous Analysis of MiRNA-mRNA in Human Meningiomas by Integrating Transcriptome: A Relationship Between PTX3 and MiR-29c

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2017 Mar 23

PMID 28327132

Citations 18

Authors

Altay Burak Dalan

Sukru Gulluoglu

Emre Can Tuysuz

Aysegul Kuskucu

Cumhur Kaan Yaltirik

Oguz Ozturk

Ugur Ture

Omer Faruk Bayrak

Affiliations

Soon will be listed here.

Abstract

Background: Although meningioma is a common disease, there is a lack of understanding of the underlying molecular mechanisms behind its initiation and progression. We used combined miRNA-mRNA transcriptome analysis to discover dysregulated genes and networks in meningiomas.

Methods: Fourteen fresh-frozen meningioma samples and one human meningeal cell line were analyzed by using miRNA and whole transcriptome microarray chips. Data was filtered and analyzed. Candidate miRNAs and mRNAs were selected for validation in fifty-eight patient samples. miRNA and target mRNA relationships were assessed by inhibiting miRNA in meningioma cells. Apoptosis and viability assays were also used as functional tests.

Results: With the whole transcriptome microarray, 3753 genes were found to be dysregulated, and 891 miRNAs were found to be dysregulated as a result of miRNA microarray. Results were combined and analyzed with bioinformatics tools. Top differential pathways included those of inflammation, cancer, and cellular growth and survival. The oncosupressor PTX3 was constitutively low in meningioma samples. Moreover, PTX3 negatively correlated with miR-29c in our samples. Inhibiting miR-29c upregulated the PTX3 level, induced apoptosis of meningioma cells, and decreased cell viability. CABIN1, miR-29c, TMOD1, PTX3, RPL22, SPARCL1 and RELA were correlated with clinicopathological features in patient samples.

Conclusions: Our results present the first integrated mRNA-miRNA analysis in meningiomas. miR-29c-3p and PTX3 are inversely correlated in tissues and meningioma cells, hinting that PTX3 can be regulated by miR-29c-3p. Furthermore, we determined potential clinicopathological markers.

Citing Articles

MicroRNAs in meningiomas: Potential biomarkers and therapeutic targets.

Beylerli O, Ilyasova T, Shi H, Sufianov A Noncoding RNA Res. 2024; 9(3):641-648.

PMID: 38577017 PMC: 10987300. DOI: 10.1016/j.ncrna.2024.02.011.

Unraveling the Impact of in Glial Tumors and Cerebral Metastases: A Step Towards Enhanced Diagnosis and Prognosis.

Turk O, Demirel N, Yaltirik C, Kaya M, Sahin O, Yilmaz S In Vivo. 2024; 38(2):652-656.

PMID: 38418125 PMC: 10905478. DOI: 10.21873/invivo.13485.

Study of lncRNAs in Pediatric Neurological Diseases: Methods, Analysis of the State-of-Art and Possible Therapeutic Implications.

Pandini C, Rey F, Cereda C, Carelli S, Gandellini P Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004481 PMC: 10675345. DOI: 10.3390/ph16111616.

Expression of miRNA-451 and miRNA-885 in Meningiomas.

Baran O, Karaoglu A, Kara E, Budun O, Katar S, Yilmaz S In Vivo. 2023; 37(6):2473-2479.

PMID: 37905647 PMC: 10621404. DOI: 10.21873/invivo.13354.

MicroRNAs miR-16 and miR-519 control meningioma cell proliferation overlapping transcriptomic programs shared with the RNA-binding protein HuR.

Hergalant S, Casse J, Oussalah A, Houlgatte R, Helle D, Rech F Front Oncol. 2023; 13:1158773.

PMID: 37601663 PMC: 10433742. DOI: 10.3389/fonc.2023.1158773.

References

Bargaje R, Gupta S, Sarkeshik A, Park R, Xu T, Sarkar M . Identification of novel targets for miR-29a using miRNA proteomics. PLoS One. 2012; 7(8):e43243. PMC: 3428309. DOI: 10.1371/journal.pone.0043243. View

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G . Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer. 2004; 114(2):249-56. DOI: 10.1002/ijc.20733. View

Rubin G, Herscovici Z, Laviv Y, Jackson S, Rappaport Z . Outcome of untreated meningiomas. Isr Med Assoc J. 2011; 13(3):157-60. View

Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James M . Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol. 2009; 29(21):5923-40. PMC: 2772747. DOI: 10.1128/MCB.00332-09. View

Kim Y, Kim H, Park D, Jeoung D . miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3. Mol Cells. 2015; 38(6):562-72. PMC: 4469914. DOI: 10.14348/molcells.2015.0051. View

Matsuo M, Nakada C, Tsukamoto Y, Noguchi T, Uchida T, Hijiya N . MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol Cancer. 2013; 12:15. PMC: 3646694. DOI: 10.1186/1476-4598-12-15. View

Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E . MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007; 104(40):15805-10. PMC: 2000384. DOI: 10.1073/pnas.0707628104. View

Carvalho L, Smirnov I, Baia G, Modrusan Z, Smith J, Jun P . Molecular signatures define two main classes of meningiomas. Mol Cancer. 2007; 6:64. PMC: 2173907. DOI: 10.1186/1476-4598-6-64. View

10.

Kunes P, Holubcova Z, Kolackova M, Krejsek J . Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012; 2012:920517. PMC: 3337627. DOI: 10.1155/2012/920517. View

11.

Daigo K, Mantovani A, Bottazzi B . The yin-yang of long pentraxin PTX3 in inflammation and immunity. Immunol Lett. 2014; 161(1):38-43. PMC: 7112810. DOI: 10.1016/j.imlet.2014.04.012. View

12.

Watson M, Gutmann D, Peterson K, Chicoine M, Kleinschmidt-DeMasters B, Brown H . Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol. 2002; 161(2):665-72. PMC: 1850745. DOI: 10.1016/S0002-9440(10)64222-8. View

13.

Shibuya M . Pathology and Molecular Genetics of Meningioma: Recent Advances. Neurol Med Chir (Tokyo). 2015; 55 Suppl 1:14-27. View

14.

Zhi F, Zhou G, Wang S, Shi Y, Peng Y, Shao N . A microRNA expression signature predicts meningioma recurrence. Int J Cancer. 2012; 132(1):128-36. DOI: 10.1002/ijc.27658. View

15.

Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P . PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015; 160(4):700-714. DOI: 10.1016/j.cell.2015.01.004. View

16.

Kalamarides M, Stemmer-Rachamimov A, Niwa-Kawakita M, Chareyre F, Taranchon E, Han Z . Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene. 2011; 30(20):2333-44. DOI: 10.1038/onc.2010.609. View

17.

Riemenschneider M, Perry A, Reifenberger G . Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006; 5(12):1045-54. DOI: 10.1016/S1474-4422(06)70625-1. View

18.

Roser F, Nakamura M, Bellinzona M, Rosahl S, Ostertag H, Samii M . The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol. 2004; 57(10):1033-7. PMC: 1770447. DOI: 10.1136/jcp.2004.018333. View

19.

Sasaki T, Hankins G, Helm G . Comparison of gene expression profiles between frozen original meningiomas and primary cultures of the meningiomas by GeneChip. Neurosurgery. 2003; 52(4):892-8; discussion 898-9. DOI: 10.1227/01.neu.0000053368.73552.bb. View

20.

Bi W, Abedalthagafi M, Horowitz P, Agarwalla P, Mei Y, Aizer A . Genomic landscape of intracranial meningiomas. J Neurosurg. 2016; 125(3):525-35. DOI: 10.3171/2015.6.JNS15591. View